Last edition
News about "Dr Joerg Koglin"
Merck Showcases New Cardio-Pulmonary Data at ACC.26
Merck presented late-breaking data from phase-III and phase-II trials at ACC.26, highlighting advances in its cardio-pulmonary pipeline, including an investigational oral PCSK9 inhibitor and therapies for pulmonary hypertension.
Dr Joerg Koglin | 17/03/2026 | By News Bureau | 102
WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension
Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.
Dr Joerg Koglin | 29/10/2025 | By Dineshwori | 255
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy